# Comparing Glycopyrronium/Formoterol Combination Therapy With Monotherapy in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD): A Narrative Review

## TL;DR

This review compares the effectiveness and safety of a combination therapy (Glycopyrronium and Formoterol) versus monotherapy in treating moderate-to-severe COPD.

## Contribution

The study provides a comprehensive analysis of combination therapy's benefits over monotherapy in COPD treatment.

## Key findings

- Combination therapy improves lung function and symptom control compared to monotherapy.
- It may reduce exacerbation rates and enhance health-related quality of life in COPD patients.
- Safety profiles of combination therapy are comparable to monotherapy with no major adverse events.

## Abstract

Chronic obstructive pulmonary disease (COPD) imposes a significant burden on individuals and healthcare systems globally. While bronchodilators, such as glycopyrronium and formoterol, are cornerstone therapies for COPD management, combining these agents has gained attention for potentially improving outcomes compared to monotherapy. This comprehensive review aims to assess the efficacy and safety of glycopyrronium/formoterol (GFF) combination therapy versus glycopyrronium monotherapy in patients with moderate-to-severe COPD. Through a systematic evaluation of clinical trials and real-world evidence, we analyze the impact of combination therapy on lung function, symptom control, exacerbation rates, and health-related quality of life (HRQoL). Furthermore, we examine the safety profile of combination therapy, including adverse cardiovascular and respiratory events. Comparative analyses with glycopyrronium monotherapy provide insights into the relative benefits and considerations for treatment selection. Factors influencing treatment choice and future directions in COPD management are also discussed. This review underscores the potential of combination therapy in optimizing COPD treatment outcomes and highlights areas for further research and clinical practice refinement.